El riesgo de eventos cardiovasculares y celecoxib: una revisión sistemática y meta-análisis

Categoría Resumen estructurado de revisiones sistemáticas
RevistaDatabase of Abstracts of Reviews of Effects (DARE)
Año 2007
Cargando información sobre las referencias

CRD SUMMARY:

This review assessed the evidence for an increased risk of cardiovascular events associated with the cyclooxygenase-2 inhibitor celecoxib. The review included a number of large trials addressing diverse conditions and found that celecoxib was associated with a higher risk of myocardial infarction than placebo or any other treatment. Despite some poorly reported methodology, this conclusion is likely to be reliable.
Epistemonikos ID: 1777ff99ced26c4dd97022a4821bac6ec76ba2c8
First added on: Jun 08, 2012